Navigation Links
Innocoll Announces Closing of $30 Million Equity Financing Investment
Date:12/17/2007

ng with Dr. Myers and his team on the product portfolio, which has both compelling therapeutic benefits and strong commercial potential" said Courtney Carson, an analyst at Camulos Capital LP and a newly appointed Director of Innocoll, Inc.

NewSmith Financial Products LLP and Sudbrook Associates LLP acted as financial advisor to Innocoll in this transaction.

About Innocoll, Inc.

Innocoll is a privately held, specialty pharmaceutical company focused on biodegradable surgical implants and topically applied healthcare products. It develops and manufactures a range of pharmaceutical products and medical devices using its proprietary collagen-based technologies, CollaRx(R) and Liquicoll(R). The Company is internationally-based with Corporate Headquarters in the United States, Research & Development and Product Commercialization Divisions in Ireland, and manufacturing facilities in Germany and South Africa.

Innocoll's lead product, GENTAMICIN SURGICAL IMPLANT, is a fully biodegradable, leave-behind surgical implant impregnated with the broad spectrum aminoglycoside antibiotic, gentamicin. It was developed using Innocoll's proprietary collagen-based drug delivery technology, CollaRx, and is designed to provide a high localized concentrations of gentamicin at the target tissue. The product is indicated as an adjunct to systemic antibiotic therapy for the prevention of surgical site infections and for the treatment of deep, localized infections in both hard and soft tissues. There are more than 60 prospective clinical trials and published case reports totaling over 7,500 patients documenting safety and efficacy over a broad range of orthopedic, colorectal, cardiothoracic, vascular, and neurosurgical procedures. The product is already approved for sale in 49 countries spanning Europe, Latin America, Middle East, Africa and Asia and is marketed under the following trade names; COLLATAMP(R) G, COLLATAMP(R) EG, SULMYCIN(R)
'/>"/>

SOURCE Innocoll, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2008)..., part of Life Technologies Corporation (NASDAQ:LI...h and discovery solutions, today announced that it... the SOLiD™ System, has been named the Life ...entist, a leading scientific publication focused o...ement of the first-ever Life Science Innovation of...
(Date:12/3/2008)...nd secondhand smoke, an estimated ten percent of p...f a developing baby to harmful cigarette byproduct...000 newborns each year and poses a significant hea...s kind, a team of researchers has completed a glob... better understand the fetal health risks from smo...
(Date:12/3/2008)...FirstCall/ -- GlaxoSmithKline,(LSE/NYSE: GSK ) ...ating to a,pending lawsuit in the previously anno...ding shares of common stock of Genelabs Technologi...n cash without interest and less any,required wit...completion of the tender offer that there not be,...
(Date:12/3/2008)...-- Cellectricon, a leading,provider of screening ...,signing of a collaborative agreement with The Aut...s of advanced automated systems for cell culture, ...pplications. Under the agreement,TAP will co-deve...ectricon,s,next generation high throughput ion ch...
Breaking Biology Technology: Applied Biosystems SOLiD System Named Life Science Innovation of the Year : The Scientist Magazine Cites the Technology's High Throughput, Lower Sequencing Cost, and Rapid Technology Innovation for Unlocking New Approaches to Clinical Research 2 Applied Biosystems SOLiD System Named Life Science Innovation of the Year : The Scientist Magazine Cites the Technology's High Throughput, Lower Sequencing Cost, and Rapid Technology Innovation for Unlocking New Approaches to Clinical Research 3 Applied Biosystems SOLiD System Named Life Science Innovation of the Year : The Scientist Magazine Cites the Technology's High Throughput, Lower Sequencing Cost, and Rapid Technology Innovation for Unlocking New Approaches to Clinical Research 4 Applied Biosystems SOLiD System Named Life Science Innovation of the Year : The Scientist Magazine Cites the Technology's High Throughput, Lower Sequencing Cost, and Rapid Technology Innovation for Unlocking New Approaches to Clinical Research 5Cutting the cord to determine babies' health risk from toxic exposure 2Cutting the cord to determine babies' health risk from toxic exposure 3Cutting the cord to determine babies' health risk from toxic exposure 4GlaxoSmithKline Announces Waiver of a Condition to the Tender Offer for Genelabs Technologies, Inc. 2GlaxoSmithKline Announces Waiver of a Condition to the Tender Offer for Genelabs Technologies, Inc. 3Cellectricon Partners With The Automation Partnership - Bringing Next Generation Ion Channel Screening System to Market. 2Cellectricon Partners With The Automation Partnership - Bringing Next Generation Ion Channel Screening System to Market. 3
...ely following the progress of the Health Insuranc...electronic health records for the last eight month... dentist with a small healthcare business, I have ...all a "stakeholder" in this exciting and promising...re important than my job, I am a husband and fathe...
...- BellBrook Labs has been awarded two federal gran...opment of its enzyme screening product. , ,The bio... screening tools for the drug-therapy market, said...l Business Innovation Research (SBIR) awards. Hig...ct millions of biochemical, genetic, or pharmacolo...
...- An education research team at the University of...he MacArthur Foundation to study the impact of d...acy. , ,MacArthur,s total $50 million investment ...cts of the digital revolution and its educational ...actually trying to do, with this grant to us, is e...
...eek in Austin , Dallas , and Boston , getting a...art ups. (Yep, you guessed it, the search for DEMO...h of what I saw was quite impressive. It was also ...lley . , ,Where Silicon Valley is at the apex of ...dership in IT systems management. In Dallas, I fou...
Other Biology Technology:Careful with that electronic health record, Mr. Leavitt 2Careful with that electronic health record, Mr. Leavitt 3Careful with that electronic health record, Mr. Leavitt 4Grants worth $800,000 help BellBrook Labs develop products 2UW gets $3M to explore educational gaming 2UW gets $3M to explore educational gaming 3What makes Silicon Valley so different? 2What makes Silicon Valley so different? 3What makes Silicon Valley so different? 4
(Date:12/4/2008)...en want younger women, often touting their intelli...earch at Gothenburg University and Oxford Universi...en and women choose partners. , Research in the ...theories about how men and women choose their part... place more emphasis on attractive appearance, whe...
(Date:12/3/2008)...nes, deputy executive director of the Internationa...tlook 2008" Dec. 9 at Rice University,s Baker Inst...ch questions as: Is the world facing a supply crun...at type of post-Kyoto policy framework might stabi... and what impact might such a policy framework hav...
(Date:12/3/2008)...re. December 3, 2008. The first 5-year forest inve... is now available to the public: Oregon,s Forest R...d Analysis Report. , Here are some key findings ... 30 million acres; about half of Oregon,s total la...ng converted to other uses particularly near urban...
(Date:12/3/2008)...-- A Duke University study suggests that evolution... the dogs depend on an energy-efficient style of f...eir prey, cats seem to have evolved a profoundly i...e or bird in slow motion. , "It is usually assum...said Daniel Schmitt, a Duke associate professor of...
Breaking Biology News(10 mins):Myth about 'dirty old men' supported by science 2'World Energy Outlook' to be presented at Rice University Dec. 9 2Forest inventories in Oregon include more than trees 2Forest inventories in Oregon include more than trees 3Dogs chase efficiently, but cats skulk counterintuitively 2Some Iraq War Vets Suffer Breathing Problems 19978 1Some Iraq War Vets Suffer Breathing Problems 19978 2Some Iraq War Vets Suffer Breathing Problems 19978 3Emerging Capital Partners Invests 2447 3 Million in North African Personal Care Company 19973 1Emerging Capital Partners Invests 2447 3 Million in North African Personal Care Company 19973 2FDA Accepts Zingo 28TM 29 Supplemental New Drug Application to Reduce Pain Associated With Peripheral Needle Insertion Procedures in Adults 5547 1FDA Accepts Zingo 28TM 29 Supplemental New Drug Application to Reduce Pain Associated With Peripheral Needle Insertion Procedures in Adults 5547 2FDA Accepts Zingo 28TM 29 Supplemental New Drug Application to Reduce Pain Associated With Peripheral Needle Insertion Procedures in Adults 5547 3FDA Accepts Zingo 28TM 29 Supplemental New Drug Application to Reduce Pain Associated With Peripheral Needle Insertion Procedures in Adults 5547 4Low intensity case management cuts COPD related hospital visits in half 19966 1Low intensity case management cuts COPD related hospital visits in half 19966 2
...omparison of equipment that can analyze the expres...etic "fingerprint," suggests these different micro...t. , Published in the May 2005 issue of Nature Me... of information generated by these systems might a...systems are used by many different laboratories. ,...
...he University of Liverpool have discovered how the...f Europeans resistant to HIV. Scientists have know...etic mutation (known as CCR5-delta32) that prevent...system but have been unable to account for the hig... low levels in areas bordering the Mediterranean. ...
...of North Carolina at Chapel Hill is one of five cl...e National Institutes of Health to study why good ...ring the next seven years, the Drug-Induced Liver ...have suffered severe liver injury caused by prescr...al supplements, alternative medicines and herbals....
... microarray analyses result in many differentially...for the biological process of interest. In order t...publications from MEDLINE were identified in which... with specific keywords were co-mentioned. , MEDLI... keywords were generated and validated. PubMed IDs...
Other Biology News:Different microarray systems more alike than previously thought 2Different microarray systems more alike than previously thought 3First North American Encapsulated Islet Transplant without Long-term Immune Suppression into a Patient with Type 1 Diabetes 2UNC launches study of liver injury caused by drugs 2
PGF1α-d4 contains 4 deuterium atoms at the 3, 3', 4, and 4' positions. It is intended for use as an internal standard for the quantification of PGF1α by GC- or LC-mass spectrometry.
II Plate Washer (Classic) from GE Healthcare, formerly Amersham Biosciences
PGD2-d4 contains 4 deuterium atoms at the 3, 3', 4, and 4' positions. It is intended for use as an internal standard for the quantification of PGD2 by GC- or LC-mass spectrometry.
Antibodies were affinity purified using epitopes specific to PPP1CC immobilized on solid support.
Biology Products: